162 related articles for article (PubMed ID: 9694740)
21. Patho-anatomical features of the bone marrow.
Lennert K; Nagai K; Schwarze EW
Clin Haematol; 1975 Jun; 4(2):331-51. PubMed ID: 1102191
[No Abstract] [Full Text] [Related]
22. Acute myeloid leukemia evolving from polycythemia vera in a patient treated with hydroxyurea.
Pulik M; Lionnet F; Genet P; Petitdidier C; Jary L; Touahri T
Am J Hematol; 1996 Nov; 53(3):207-8. PubMed ID: 8895700
[No Abstract] [Full Text] [Related]
23. Effects of chemotherapy (busulfan-hydroxyurea) and interferon-alfa on bone marrow morphologic features in chronic myelogenous leukemia. Histochemical and morphometric study on sequential trephine biopsy specimens with special emphasis on dynamic features.
Thiele J; Kvasnicka HM; Schmitt-Graeff A; Bundschuh S; Biermann T; Roessler G; Wasmus M; Diehl V; Zankovich R; Schaefer HE
Am J Clin Pathol; 2000 Jul; 114(1):57-65. PubMed ID: 10884800
[TBL] [Abstract][Full Text] [Related]
24. Leukemic transformation in myeloproliferative neoplasms: therapy-related or unrelated?
Björkholm M; Hultcrantz M; Derolf ÅR
Best Pract Res Clin Haematol; 2014 Jun; 27(2):141-53. PubMed ID: 25189725
[TBL] [Abstract][Full Text] [Related]
25. Cytogenetic response to pipobroman in Philadelphia-positive chronic myeloid leukemia with thrombocythemic onset.
Orlandi E; Bernasconi P; Boni M; Calatroni S; Lazzarino M
Ann Hematol; 2005 Feb; 84(2):127-8. PubMed ID: 15378276
[No Abstract] [Full Text] [Related]
26. Leukemia and myelodysplasia effect of multiple cytotoxic therapy in essential thrombocythemia.
Randi ML; Fabris F; Girolami A
Leuk Lymphoma; 2000 Apr; 37(3-4):379-85. PubMed ID: 10752989
[TBL] [Abstract][Full Text] [Related]
27. Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980.
Kiladjian JJ; Chevret S; Dosquet C; Chomienne C; Rain JD
J Clin Oncol; 2011 Oct; 29(29):3907-13. PubMed ID: 21911721
[TBL] [Abstract][Full Text] [Related]
28. Leukemia and myelodysplasia in patients with essential thrombocythemia treated with cytotoxic agents.
Randi ML; Fabris F; Girolami A
Haematologica; 1999 Nov; 84(11):1049-50. PubMed ID: 10553169
[No Abstract] [Full Text] [Related]
29. Treatment of polycythaemia vera and essential thrombocythaemia.
Tefferi A; Silverstein MN
Baillieres Clin Haematol; 1998 Dec; 11(4):769-85. PubMed ID: 10640216
[TBL] [Abstract][Full Text] [Related]
30. [Treatment of polycythemia. II.--Comparison of hydroxyurea with pipobroman in 294 patients less than 65 years of age].
Najean Y; Rain JD; Lejeune F; Echard M; Fermand JP; Gruyer P; Brahimi S
Ann Med Interne (Paris); 1998 Mar; 149(2):94-100. PubMed ID: 11490531
[TBL] [Abstract][Full Text] [Related]
31. Emergence of chronic myelogenous leukemia in a patient with primary thrombocythemia and absence of BCR/ABL rearrangement.
Cesar JM; Cabello P; Ferro T; Navarro JL
Cancer Genet Cytogenet; 2006 May; 167(1):74-7. PubMed ID: 16682291
[TBL] [Abstract][Full Text] [Related]
32. [Essential thrombocythemia: conventional therapy].
Grossi A; Vannucchi AM; Longo G; Rafanelli D; Rossi Ferrini P
Haematologica; 1991 Jun; 76 Suppl 3():368-70. PubMed ID: 1752534
[No Abstract] [Full Text] [Related]
33. Efficacy trial of pipobroman in essential thrombocythemia: a study of 24 patients.
Brusamolino E; Canevari A; Salvaneschi L; Merante S; Bernasconi C
Cancer Treat Rep; 1984 Nov; 68(11):1339-42. PubMed ID: 6541969
[TBL] [Abstract][Full Text] [Related]
34. Myelodysplastic syndrome and secondary acute leukemia after treatment of essential thrombocythemia with hydroxyurea.
van den Anker-Lugtenburg PJ; Sizoo W
Am J Hematol; 1990 Feb; 33(2):152. PubMed ID: 2301374
[No Abstract] [Full Text] [Related]
35. Busulfan for the treatment of myeloproliferative neoplasms: the Mayo Clinic experience.
Begna K; Abdelatif A; Schwager S; Hanson C; Pardanani A; Tefferi A
Blood Cancer J; 2016 May; 6(5):e427. PubMed ID: 27232929
[No Abstract] [Full Text] [Related]
36. Long-term and low-dose of busulfan is a safe and effective second-line treatment in elderly patients with essential thrombocythemia resistant or intolerant to hydroxyurea.
Renso R; Aroldi A; Pioltelli P; Gambacorti-Passerini C; Elli EM
Blood Cancer J; 2018 Jun; 8(6):56. PubMed ID: 29891835
[No Abstract] [Full Text] [Related]
37. Dysplasia of all granulocyte lineages in myelodysplastic evolution of essential thrombocythemia.
Bain BJ; Garnett C; Deplano S; Naresh K; Kanfer E
Am J Hematol; 2013 May; 88(5):426. PubMed ID: 23460316
[No Abstract] [Full Text] [Related]
38. Treatment strategies in essential thrombocythemia. A critical appraisal of various experiences in different centers.
Barbui T; Finazzi G; Dupuy E; Kiladjian JJ; Brière J
Leuk Lymphoma; 1996 Sep; 22 Suppl 1():149-60. PubMed ID: 8951786
[TBL] [Abstract][Full Text] [Related]
39. [Essential thrombocythemia, chronic myeloid leukemia or polycythemia vera].
GOUDSMIT R
Ned Tijdschr Geneeskd; 1956 Apr; 100(17):1236-9. PubMed ID: 13322104
[No Abstract] [Full Text] [Related]
40. Primary thrombocythemia.
Jamshidi K; Ansari A; Windschitl HE; Swaim WR
Geriatrics; 1973 Jan; 28(1):121-33. PubMed ID: 4539498
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
